Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19349021 | 1.00 | NAMPT (0.58) | NAMPTRAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL1707501 | 0.94 | RAB9A (0.63) | NAMPTRAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL17865782 | 0.91 | NAMPT (0.58) | NAMPTRAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL23911908 | 0.86 | RAB9A (0.54) | NAMPTRAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL10912509 | 0.86 | NPC1 (0.57) | RAB9ANPC1SMN1; SMN2GAAKMT2A | |
| SCHEMBL17426746 | 0.85 | RAB9A (0.50) | NAMPTRAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL26699525 | 0.84 | NAMPT (0.53) | NAMPTRAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL7121699 | 0.84 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2GAAKMT2A | |
| SCHEMBL25970067 | 0.84 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2GAAKMT2A | |
| SCHEMBL255251 | 0.83 | GAA (0.76) | RAB9ANPC1SMN1; SMN2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8672466-B2 | Ink composition, ink set and image forming method | FUJIFILM CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20130243720-A1 | Iron(II)-Containing A Treatments for Hyperphosphatemia | HUVAL CHAD (US) | 2013-09-19 | — | — | US | disclosed |
| US-20120069084-A1 | INK COMPOSITION, INK SET AND IMAGE FORMING METHOD | FUJIFILM CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100135950-A1 | Iron(II)-Containing Treatments for Hyperphosphatemia | GENZYME CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135950-A1 | Iron(II)-Containing Treatments for Hyperphosphatemia | FECH, SLC20A2, SDHB | NAMPT 866/4885RAB9A 4150/4885NPC1 1553/4885 |
| US-20130243720-A1 | Iron(II)-Containing A Treatments for Hyperphosphatemia | SLC20A2, PFKFB2, SLC46A1 | NAMPT 811/4885RAB9A 3831/4885NPC1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.